
uniQure N.V. (NASDAQ:QURE) on Friday released initial safety and exploratory efficacy data from the first cohort of its Phase 1/2a trial of AMT-191, an investigational gene therapy for Fabry disease.
Fabry disease is a genetic lysosomal storage disorder characterized by a deficiency of the enzyme that breaks down fats.